CDH1 Mutations Bring High Gastric Cancer Risk


According to a large study, men with a CDH1 gene mutation have a 70% incidence of gastric cancer by the age of 80 years and women have a 56% incidence.

The researchers found 16 candidate mutations that could be associated with HDGC

Men who carry a mutation in the E-cadherin (CDH1) gene, a gene associated with hereditary diffuse gastric cancer (HDGC), have a 70% incidence of gastric cancer by the age of 80 years, according to a large study looking at CDH1 mutation carriers.

Women in the study were found to have a 56% incidence of gastric cancer by age 80.

These risk estimates were taken from a study, published in JAMA Oncology, by Samantha Hansford, MSc, from the Centre for Translational and Applied Genomics, British Columbia Cancer Agency, Vancouver, British Columbia, and colleagues. The researchers sought to get accurate estimates of gastric cancer risk among people carrying CDH1 mutations, and screen for additional gene mutations that might be associated with HDGC.

The study included 183 cases meeting criteria for HDGC taken from 75 mutation-positive families. The researchers performed testing for CDH1 and found 31 distinct mutations in 34 of the 183 cases (19%).

The researchers acknowledged that 19% is significantly less than that seen in earlier studies of HDGC families with CDH1 mutations.

“Our new penetrance estimates are more precise because of the larger cohort used. The families used to compile these data are from multicultural backgrounds, primarily from regions where gastric cancer is present at low incidences,” the researchers wrote “This number could be a reflection of the varied ethnicities within our consecutive series; it is well known that the frequency is highly variable between countries with different incidences of gastric cancer, and prior ascertainment of kindred with the strongest family histories may have skewed past reports.”

In participants who were CDH1-negative, the researchers analyzed for other mutations associated with HDGC and found 16 candidate mutations in 144 probands (11%). These mutations included: CTNNA1, BRCA2, STK11, SDHB, PRSS1, ATM, MSR1, and PALB2.

“Among the germline abnormalities uncovered in this cohort, CTNNA1 mutations are most likely to mirror the genetic and functional significance of CDH1 mutations,” Hansford and colleagues wrote. “Like CDH1, CTNNA1 is involved in intercellular adhesion and is a suspected tumor suppressor and susceptibility gene for DGC.”

In an editorial published with the study, James M. Ford, MD, from Stanford University School of Medicine, wrote that the research by Hansford et al is a “major advance.”

“Of note, in the study by Hansford et al, only 19% of families meeting clinical criteria for HDGC were found to have a pathogenic germline CDH1 mutation, with another 2% exhibiting a variant of uncertain significance,” Ford wrote. “This is significantly less than previously described, but regardless, emphasizes the point well known to cancer genetics practitioners that we cannot account genetically for the majority of HDGC families through CDH1 testing and that only a handful of true gastric cancer families are associated with mutations in genes for Lynch syndrome, Li-Fraumeni syndrome, Cowden disease, Peutz-Jeghers syndrome, and a few others.”

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content